{"id":"W4213022323","doi":"10.1200/jco.2022.40.6_suppl.tps405","title":"TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Internal medicine; Adverse effect; Oncology; Phases of clinical research; Randomized controlled trial; Urology; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003292263,0.002608698,0.002703821,0.0005655158,0.0007963277,0.001522858,0.001649818,0.002459352,0.009837628],"category_scores_gemma":[0.00200525,0.001155919,0.002156633,0.0005802966,0.001310945,0.001749649,0.000476537,0.004304633,0.002109034],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001655629,"about_ca_system_score_gemma":0.003527062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001630025,"about_ca_topic_score_gemma":0.005798663,"domain_scores_codex":[0.9991303,0.0004322481,0.00004888093,0.0001593685,0.00007982171,0.0001494522],"domain_scores_gemma":[0.9987349,0.0001770677,0.0002932993,0.00006733287,0.0001086642,0.0006187901],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9606231,0.01610944,0.001411579,0.0007293716,0.001141898,0.00009260113,0.00008510794,0.0003103331,0.004783689,0.0001721715,0.00328759,0.01125299],"study_design_scores_gemma":[0.9539534,0.04253607,0.001478817,0.00002529786,0.0002538401,0.00004370624,0.00001870385,0.0002336719,0.0003044457,0.0001246519,0.001015289,0.00001218755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9123025,0.008753293,0.002589046,0.002919912,0.001647508,0.04999383,0.01287123,0.0006970735,0.008225555],"genre_scores_gemma":[0.9259945,0.004015788,0.006214484,0.005450546,0.0007955131,0.03909162,0.009613187,0.0001148513,0.008709532],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009837628,"threshold_uncertainty_score":0.03291017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1470246963203128,"score_gpt":0.4409735268817561,"score_spread":0.2939488305614434,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}